- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04348604
Improving Adherence in Adolescents and Young Adults With Bipolar Disorder (IGNITE)
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- University of Cincinnati
-
Cleveland, Ohio, United States, 44106
- Case Western Reserve Universty
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- DSM-5 diagnosis of bipolar disorder (BD), type I or II as diagnosed by the Structured Clinical Interview for DSM-5 (SCID-5)
- Poor adherence defined as missing ≥ 20% of prescribed evidence-based BD medications, i.e., mood stabilizer (e.g., lithium, valproic acid, or carbamazepine) or second generation antipsychotics, on the TRQ for the past week or past month
- If < 18 years, able and willing to give written informed assent and have a legal guardian provide written informed consent; if > 18 years, able and willing to provide written informed consent
- Fluent in English
Exclusion Criteria:
- Unable to receive care in the outpatient setting due to illness severity
- A DSM-5 diagnosis of an autism spectrum disorder or primary psychotic disorder
- Documented or suspected IQ < 70
- Prior enrollment in CAE or Phase 2
- Have recently (in the past month) started a new psychotherapy/behavioral intervention
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Customized Adherence Enhancement for AYA
This arm will receive the experimental intervention, Customized Adherence Enhancement for Adolescents and Young Adults (CAE-AYA).
|
Customized Adherence Enhancement for Adolescents and Young Adults (CAE-AYA): CAE-AYA participants will have 4 core in-person sessions (45-60 minutes each) spaced about 1 week apart over a period of approximately 4 weeks and one "booster" in-person session approximately 4 weeks after completion of the 4 core sessions (total of up to 5 in-person sessions spaced out over 8 weeks).
There will be one follow-up phone call with a study interventionist, approximately 6 weeks post-baseline (timed half-way between completion of the core sessions and the "booster" session).
All AYAs assigned to the CAE-AYA arm will receive all 4 modules (Psychoeducation on BD Medications; Communication with Providers & Caregivers; Medication Routines; and Targeting Risky Behavior via Modified Motivational Enhancement Therapy (MET)), with the content within each module being customized to developmental stage and behavioral experience.
|
Active Comparator: Enhanced Treatment as Usual (ETAU)
This arm will receive the control intervention, Enhanced Treatment as Usual (ETAU).
|
Enhanced Treatment as Usual (ETAU): ETAU will consist of usual clinical care with prescribing clinicians and therapists, augmented by written materials specific to BD for AYAs and 6 follow-up telephone calls to briefly review the materials and be available for questions by social workers with mental health experience and at least some experience in working with AYA with BD.
In order to ensure that there is not treatment contamination, different trained interventionists will be used for CAE and eTAU.
Therapists will briefly review the materials and be available for questions during the phone calls.
Materials will cover general self-management in BD.
The calls will be relatively brief (maximum of 20-30 minutes).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in the Tablet Routine Questionaire (TRQ) "past month" item at 24 weeks
Time Frame: Baseline and 24 weeks
|
The TRQ "past month" item is a subject report of the percentage of prescribed medications not taken within the past month.
|
Baseline and 24 weeks
|
Change from baseline in the Tablet Routine Questionaire (TRQ) "past week" item at 24 weeks
Time Frame: Baseline and 24 weeks
|
The TRQ "past week" item is a subject report of the percentage of prescribed medications not taken within the past week.
|
Baseline and 24 weeks
|
Change from baseline in treatment adherence as measured by special pill counter at 24 weeks
Time Frame: Baseline and 24 weeks
|
A special pill cap/box will record the time/date of bottle opening.
A dose will be counted as "taken" if the bottle is opened within two hours of the prescribed time.
A percent of doses taken (treatment adherence) will be calculated by dividing the number of times the bottle is opened by the number of times it should have been opened as per the prescription.
|
Baseline and 24 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Martha Sajatovic, MD, Case Western Reserve University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- R34MH117206 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Data entered into the NIMH National Database: We will collaborate with our project office to determine the best mechanism to ensure that our Phase 3 data is entered into the common informatics platform by NIMH, called the National Database for Clinical Trials Related to Mental Illness (http://ndct.nimh.nih.gov, NDCT). We will work with NIMH to transform the data we collect into relevant information using the suggested consent form language, NIMH software that will create global unique identifiers and a useful data dictionary as much as we are able in order to deposit data into the National Database allowing other researchers and NIMH to use available data.
In line with accepted data sharing practices and ethical principles, we will share de-identified raw data with other researchers attempting to replicate our findings or including our findings in subsequent projects.
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bipolar Disorder
-
ProgenaBiomeRecruitingBipolar Disorder | Bipolar I Disorder | Bipolar II Disorder | Bipolar Type I Disorder | Bipolar Disorder Mild | Bipolar Disorder Moderate | Bipolar Disorder SevereUnited States
-
Rush University Medical CenterThe Ryan Licht Sang Bipolar FoundationCompletedBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar Disorder I | Bipolar Affective DisorderUnited States
-
University of PittsburghNational Alliance for Research on Schizophrenia and DepressionCompletedBipolar I Disorder | Bipolar II Disorder | Bipolar Disorder NOSUnited States
-
Region StockholmKarolinska InstitutetRecruitingBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II Disorder | Bipolar Affective Disorder; Remission in | Bipolar Affective Disorder, Currently Depressed, ModerateSweden
-
Hospital de Clinicas de Porto AlegreFederal University of Rio Grande do Sul; Hospital Moinhos de VentoActive, not recruitingBipolar Disorder | Bipolar Depression | Major Depressive Disorder | Bipolar I Disorder | Affective Disorder | Bipolar II DisorderBrazil
-
Medical University of South CarolinaMilken InstituteCompletedBipolar Disorder | Bipolar I Disorder | Bipolar II DisorderUnited States
-
Joshua RosenblatRecruitingBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II DisorderCanada
-
Mayo ClinicCompletedMajor Depressive Disorder, Bipolar I and Bipolar IIUnited States
-
Joshua RosenblatRecruitingBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II DisorderCanada
-
Myriad Genetic Laboratories, Inc.University of MinnesotaCompletedMajor Depressive Disorder, Bipolar I and Bipolar IIUnited States
Clinical Trials on Customized Adherence Enhancement for Adolescents and Young Adults (CAE-AYA)
-
Martha SajatovicMerck Sharp & Dohme LLCRecruiting
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI)Recruiting
-
Medical University of South CarolinaUniversity of Colorado, Denver; Indiana University School of Medicine; Oregon...RecruitingPTSD | Substance Use DisordersUnited States
-
Columbia UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruiting
-
Case Western Reserve UniversityNational Institute of Mental Health (NIMH)CompletedSchizophrenia | Schizo Affective Disorder | Medication NonadherenceTanzania
-
Martha SajatovicOtsuka Pharmaceutical Development & Commercialization, Inc.CompletedBipolar Disorder | Medication Adherence | Medication Non AdherenceUnited States
-
University Hospitals Cleveland Medical CenterCompletedPsychotic Disorders | Schizophrenia | Schizoaffective Disorder | Medication Adherence | Medication Non-AdherenceUnited States